You are here » Home » Companies » Company Overview » Cadila Healthcare Ltd

Cadila Healthcare Ltd.

BSE: 532321	Sector: Health care
NSE: CADILAHC	ISIN Code: INE010B01027

BSE 00:00 | 08 Mar

446.10

3.90
(0.88%)

OPEN

441.10

HIGH

451.50

LOW

441.10

NSE 00:00 | 08 Mar

446.20

3.95
(0.89%)

OPEN

443.00

HIGH

451.50

LOW

442.00

Add to Watchlist | Add to Portfolio

OPEN	441.10
PREVIOUS CLOSE	442.20
VOLUME	86925
52-Week high	509.35
52-Week low	212.70
P/E	25.32
Mkt Cap.(Rs cr)	45,667
Buy Price	446.10
Buy Qty	1315.00
Sell Price	448.50
Sell Qty	100.00

OPEN	441.10
CLOSE	442.20
VOLUME	86925
52-Week high	509.35
52-Week low	212.70
P/E	25.32
Mkt Cap.(Rs cr)	45,667
Buy Price	446.10
Buy Qty	1315.00
Sell Price	448.50
Sell Qty	100.00

Click here for interactive graph

Cadila Healthcare Ltd. (CADILAHC) - Latest News & Headlines

Here is a derivative strategy for Cadila Health by Vinay Rajani of HDFC Sec

7.22 am | 15 Jan 2021 | Business Standard

The stock price of Cadila Healthcare has broken out from the consolidation which held for last three weeks
Bright outlook: Sun Pharma to Cipla, drug firms set for Q3 health boost

1.11 am | 11 Jan 2021 | Business Standard

Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportuni...
Stocks to watch: RCFL, Tata Motors, RIL, BEML, Cadila Health, Adani Green

8.39 am | 4 Jan 2021 | Business Standard

Tata Motors reported a 21 per cent increase in total vehicle sales in the domestic market to 53,430 units in December
Stocks to watch: Cadila Health, NIIT, BEML, Dish TV, RIL, DLF, Coal India

8.49 am | 28 Dec 2020 | Business Standard

The board of NIIT has approved buyback of 98.75 lakh equity shares of face value of Rs 2 each.
Nifty Pharma index hits new record high; Laurus Labs, Glenmark Pharma up 3%

10.37 am | 21 Dec 2020 | Business Standard

Cipla, Cadila Healthcare, Lupin, Sun Pharma and Aurobindo Pharma from the Nifty Pharma index were up in the range of 1 per cent to 2 per cent on the N...
BSE Healthcare index hits new high; Sun Pharma, Laurus Labs gain up to 5%

2.47 pm | 4 Dec 2020 | Business Standard

Sun Pharmaceutical Industries hit afresh 52-week high of Rs 568.50, up nearly 4 per cent in the intra-day trade today. It has surged 11 per cent in t...
Cadila Healthcare completes phase-2 trial of Hepatitis C drug for Covid-19

3.53 pm | 12 Nov 2020 | Business Standard

95% subjects in the test who received a single dose of PegiHepTM along with SOC became virus free as assessed by RT-PCR on day 14, compared to 68% of ...
Cadila Healthcare rallies 9% on strong September quarter results

9.49 am | 3 Nov 2020 | Business Standard

In Q2FY21, Cadila's Ebitda margins improved by 370 basis points at 22.6% against 18.9% in Q2FY20.
Zydus Cadila Q2 net up four-fold on surge in US sales, strong show at home

6.02 pm | 2 Nov 2020 | Business Standard

Firm prunes net debt by 40% since March 2020; consolidated income up 13%
Cadila: Rebound in domestic formulations to add to US sales, drive earnings

12.40 am | 9 Oct 2020 | Business Standard

In the US, Cadila is expected to gain from improvement in realisation for its product range led by drug shortages
Cadila Healthcare rises 4% on launch of pressurized Metered Dose Inhaler

10.48 am | 8 Oct 2020 | Business Standard

Forglyn pMDI is priced at Rs 495 per pack and has been developed in-house using Zydus' innovations in formulation technology